戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 g milestones (AMH <20 pg/mL or >12 months of amenorrhea).
2 rtal delay; bradycardia; oligomenorrhea; and amenorrhea).
3 linical hyperandrogenism, oligomenorrhea, or amenorrhea.
4 s, 16 (26%) irregular bleeding, and 16 (26%) amenorrhea.
5 lar and unpredictable bleeding, and 19 (30%) amenorrhea.
6 truation disorders; premature menopause, and amenorrhea.
7 er completion of chemotherapy, she developed amenorrhea.
8 s polycystic ovary syndrome and hypothalamic amenorrhea.
9  Low parity also predicts shorter postpartum amenorrhea.
10 ciation between breastfeeding and postpartum amenorrhea.
11 menopause in women with chemotherapy-induced amenorrhea.
12 ived chemotherapy, 35% experienced long-term amenorrhea.
13 ceive chemotherapy, 5.3% developed long-term amenorrhea.
14 e size of UFs, inhibit ovulation and lead to amenorrhea.
15 cts a genetic predisposition to hypothalamic amenorrhea.
16 oup without tamoxifen had the lowest rate of amenorrhea.
17 deficiency, are associated with hypothalamic amenorrhea.
18 nRH secretion that characterize hypothalamic amenorrhea.
19 eiving adjuvant chemotherapy are at risk for amenorrhea.
20 rehensive evaluation of chemotherapy-induced amenorrhea.
21 ine, and prednisone (BEACOPP) had continuous amenorrhea.
22 ormone leptin and may result in hypothalamic amenorrhea.
23 ndocrine function in women with hypothalamic amenorrhea.
24 g their role in women with treatment-related amenorrhea.
25 s reported regular menses, and 4.6% reported amenorrhea.
26  of the LH protein and cause anovulation and amenorrhea.
27  a teenage girl with proteinuria and primary amenorrhea.
28                                              Amenorrhea 12 months after random assignment was signifi
29  adrenal insufficiency, two had a history of amenorrhea after birth of their children many years earl
30            We determined the age of onset of amenorrhea after breast cancer for women who were and we
31                                              Amenorrhea after therapy was most pronounced in women wi
32 are treated for advanced-stage HL experience amenorrhea after therapy.
33  were assessed concerning their influence on amenorrhea: age, treatment, stage, and the use of oral c
34 ineral density in patients with hypothalamic amenorrhea, an infertility syndrome in females.
35          Body weight combined with months of amenorrhea and age of menarche predicted the BMD of the
36                                  Duration of amenorrhea and body weight of amenorrheic athletes predi
37 e for pregnancy, ascertained by a history of amenorrhea and confirmed by urine test.
38 re ovarian failure (POF) is characterized by amenorrhea and high serum levels of follicle-stimulating
39 tory menstruation in women with hypothalamic amenorrhea and improves metabolic dysfunction in patient
40 zed by fibrosis, inflammation, and can cause amenorrhea and infertility due to abnormal endometrial h
41                                              Amenorrhea and irregular cycles were associated with hig
42  with diet- or exercise-induced hypothalamic amenorrhea and lipoatrophy.
43 c hypogonadism in 55 women with hypothalamic amenorrhea and performed in vitro studies of the identif
44 a by treatment arm, the relationship between amenorrhea and QOL, and QOL by treatment arm.
45 tion in some women with chemotherapy-induced amenorrhea and should be used with caution.
46 ron donor for these enzymes, in a woman with amenorrhea and three children with ABS, even though knoc
47 iac iron was associated with the presence of amenorrhea and with NTBI levels.
48 s of prior studies of increased frequency of amenorrhea and/or irregular menstrual cycles, particular
49 ive pregnancy test, greater than 3 months of amenorrhea, and a follicle-stimulating hormone > or = 30
50 l axis such as delayed puberty, hypothalamic amenorrhea, and hypogonadotropic hypogonadism.
51 dex lt 10% for age, vitamin D insufficiency, amenorrhea, and low bone mass.
52 rual cycle length variability and periods of amenorrhea, and often symptoms such as vasomotor dysfunc
53 ent rates of permanent amenorrhea, temporary amenorrhea, and oligomenorrhea among different regimens;
54                           Disordered eating, amenorrhea, and osteoporosis describe the "female athlet
55               Chronic renal failure leads to amenorrhea, and successful pregnancy is rare.
56 he possible benefits of chemotherapy-induced amenorrhea, and the challenges of interpreting the exist
57 leptin deficiency in women with hypothalamic amenorrhea appears to improve reproductive, thyroid, and
58 troducing foods at 4 mo on the likelihood of amenorrhea at 6 mo postpartum, but not thereafter, and t
59  with lowest lifetime weight and duration of amenorrhea, but there were no such associations with bon
60 strogen-unresponsive endometrium and primary amenorrhea, but with spontaneous tubal pregnancies.
61      Prespecified analyses examined rates of amenorrhea by treatment arm, the relationship between am
62  when the patient experienced >/= 2 years of amenorrhea, commencing within 2 years of initiating chem
63 hemotherapy; (2) define chemotherapy-related amenorrhea (CRA); (3) document rates of permanent amenor
64                The risk of induced long-term amenorrhea does not seem to be greater among mutation ca
65                Eight women with hypothalamic amenorrhea due to strenuous exercise or low weight were
66 nosis and who underwent chemotherapy-induced amenorrhea during adjuvant treatment.
67 erall survival was improved in patients with amenorrhea for 6 months or more across all treatment gro
68 e-aged multiparous female who presented with amenorrhea for three months.
69 ll for more than 6 years, risk ratio = 2.7), amenorrhea (for patients who had this symptom for more t
70  the histologic features and the presence of amenorrhea, galactorrhea, and an elevated serum prolacti
71  myelopathy from syringomyelia, paraparesis, amenorrhea-galactorrhea, and other endocrine problems, h
72                                 Hypothalamic amenorrhea (HA) is associated with dysfunction of the hy
73 ystic ovary syndrome (PCOS) and hypothalamic amenorrhea (HA).
74 ovary syndrome (PCOS; n = 6) or hypothalamic amenorrhea (HA; n = 6).
75 ed ovarian follicle population, resulting in amenorrhea, hypoestrogenism, and loss of fertility befor
76      Here, we studied 3 sisters with primary amenorrhea, hypothyroidism, and hypergonadotropic hypogo
77 ries each year and many experience temporary amenorrhea immediately following injury.
78  with lowest lifetime weight and duration of amenorrhea in anorexia nervosa.
79 n exclusive breastfeeding and maintenance of amenorrhea in the early postpartum period is also found
80 ociated with an increased risk for sustained amenorrhea in these patients.
81  characterized by elevated gonadotropins and amenorrhea in women aged <40 years.
82         Chronic liver disease often leads to amenorrhea in women of childbearing age.
83 important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation.
84 riages: 72%; mean gestational age 39 days of amenorrhea) in the intention-to-treat analysis; 66.6% of
85            The incidence of hospitalization, amenorrhea, infections, nausea, and vomiting was signifi
86                   It clinically manifests as amenorrhea, infertility, and signs of estrogen insuffici
87 = 40, hyperandrogenism and oligomenorrhea or amenorrhea), intermediate (n = 8, hyperandrogenism), or
88                      Functional hypothalamic amenorrhea is a reversible form of gonadotropin-releasin
89                         Chemotherapy-induced amenorrhea is a serious concern for women undergoing can
90                                              Amenorrhea is a well-recognized occurrence after chemoth
91                                              Amenorrhea is significantly more frequent in women with
92                                  Lactational amenorrhea (LA) is associated with postpartum infertilit
93  self-report of climacteric symptoms, and/or amenorrhea lasting >6 months, and/or oophorectomy, and/o
94 in menstrual flow amount or duration; or (3) amenorrhea lasting at least 3 months.
95  for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertilit
96                          Extended periods of amenorrhea may result in low bone density at multiple sk
97 ted studies documented about the Lactational Amenorrhea Method (LAM).
98 terilisations, implants, condom, lactational amenorrhea method, vaginal barrier methods, emergency co
99 lly accepted indicators of pregnancy include amenorrhea, morning sickness, tender or tingling breasts
100                                              Amenorrhea occurred frequently as a result of treatment
101 verage of 5 years until at least 6 months of amenorrhea occurred.
102 ea were 73%, 82%, and 6%, respectively, with amenorrhea occurring within 10 days in the majority of p
103         Exercising women with oligomenorrhea/amenorrhea (Oligo/Amen) were randomly assigned to an int
104  However, the impact of chemotherapy-induced amenorrhea on prognosis is still being defined.
105 ion of hormone therapy prior to 12 months of amenorrhea (OR = 2.94, 95% CI: 1.14, 7.58; P = 0.03).
106  measures of menstrual blood loss (including amenorrhea), pain, distress from bleeding and pelvic dis
107 ous genitalia, prepubertal bleeding, primary amenorrhea, pelvic mass, and pelvic pain.
108                                              Amenorrhea rates differed significantly by treatment arm
109 ogen receptor status, and treatment regimen, amenorrhea rates on triptorelin were comparable to those
110       Six control subjects with hypothalamic amenorrhea received no treatment and were studied for a
111 rp weakening of the breastfeeding-postpartum amenorrhea relationship has globally occurred over the t
112    The slope of the breastfeeding-postpartum amenorrhea relationship is negatively associated with de
113                          Adverse events were amenorrhea (seen in 41% of the cyclophosphamide group, 4
114 s families with daughters exhibiting primary amenorrhea, short stature, and a 46,XX karyotype.
115 onadism are found in women with hypothalamic amenorrhea, suggesting that these mutations may contribu
116 drogenism), or low (n = 7, oligomenorrhea or amenorrhea) suspicion of PCOS.
117 rrhea (CRA); (3) document rates of permanent amenorrhea, temporary amenorrhea, and oligomenorrhea amo
118 etween breastfeeding duration and postpartum amenorrhea (the absence of menstruation following a birt
119 e correctly answered the three LAM criteria: amenorrhea, the first 6 months, and exclusive breast fee
120           We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced
121 als with manifestations ranging from primary amenorrhea to loss of menstrual function prior to age 40
122 ed in 7 of the 55 patients with hypothalamic amenorrhea: two variants in the fibroblast growth factor
123 or potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, h
124 of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hy
125             The rate of chemotherapy-induced amenorrhea varies with patient age and chemotherapy regi
126                Key secondary end points were amenorrhea, volume of menstrual blood loss, distress fro
127                    At follow-up, the rate of amenorrhea was 16.8% (2.9% because of pregnancy).
128                                              Amenorrhea was associated with improved survival regardl
129                   The probability of induced amenorrhea was higher for women who received tamoxifen t
130                                              Amenorrhea was significantly more frequent after dose-es
131                              Median times to amenorrhea were 7 days for patients receiving 5 mg of ul
132    The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 y
133                                 The rates of amenorrhea were 73%, 82%, and 6%, respectively, with ame
134 al Disorders, Fourth Edition, AN (except for amenorrhea) were enrolled.
135    This review will discuss the incidence of amenorrhea with commonly-used adjuvant chemotherapeutic
136 ere to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women.
137  experiencing the female triad (hypothalamic amenorrhea) with acquired chronic hypoleptinemia induced

 
Page Top